Sahajanand Medical

Sahajanand Medical Technologies was incorporated in the year 2001, embarking on a mission to advance cardiovascular care through cutting-edge medical engineering. Over the decades, the company has achieved significant milestones, most notably becoming the first manufacturer globally to secure CE certification for a drug-eluting stent with a biodegradable polymer under its flagship brand Infinnium. From its modest beginnings, the enterprise has scaled remarkably to emerge as a prominent medical device player with a footprint spanning over 76 countries across Europe, Asia, and other key international geographies.

The core business model revolves around the design, development, manufacturing, and commercialization of advanced medical devices categorized primarily into Vascular Intervention, Structural Heart, and complementary product lines. Its manufacturing and R&D pipelines are anchored by sophisticated engineering processes that produce critical devices such as the Supraflex Cruz drug-eluting stent, Hydra transcatheter aortic valve implantation systems, and Cocoon occluders. These products represent high-precision technology requiring rigorous clinical validation, complex material science expertise, and stringent quality control protocols to ensure safety and efficacy in critical cardiovascular procedures.

The company caters to a highly specialized institutional customer base comprising premier hospitals, cardiac care centers, specialized clinics, and medical distributors worldwide. Its market positioning is underpinned by robust clinical validation, with its portfolio backed by 72 comprehensive clinical studies published and recognized globally. This clinical rigor ensures high customer stickiness and strong brand recall among cardiologists and healthcare institutions who demand uncompromising performance standards for life-saving cardiovascular interventions.

Operational scale is anchored by advanced manufacturing infrastructure and dedicated research and development facilities located strategically, including key operations in India and Thailand. The R&D framework is powered by a specialized team of 102 professionals, including biomedical engineers, clinical research specialists, and regulatory experts. This talent pool drives continuous product iteration, biocompatibility testing, and next-generation device development, ensuring the company remains at the forefront of global medical technology advancements.

Led by an experienced promoter and management group, Sahajanand Medical combines deep domain expertise with strategic corporate governance. The leadership has consistently steered the company toward expanding its global distribution network, enhancing manufacturing capacities, and scaling up clinical research initiatives to capture expanding market opportunities in the global structural heart and vascular intervention sectors.

The initial public offering of Sahajanand Medical is structured through a book-built issue aggregating approximately ₹475.5 Crores, operating within a price band of ₹327 to ₹344 per equity share with a face value of ₹1 per share. The issue comprises a fresh issuance of equity shares alongside an offer for sale component, providing liquidity to existing shareholders while raising growth capital. Bidding took place from October 15 to October 19, 2026, with listing proposed on both BSE and NSE, supported by a comprehensive timeline covering allotment finalization and credit of shares.

The net proceeds from the fresh issue component are primarily earmarked to fund strategic growth initiatives, working capital requirements, debt optimization, and general corporate purposes. By reinforcing its balance sheet and securing liquidity, the company intends to accelerate its R&D roadmap for next-generation structural heart devices and expand its direct sales and distribution footprint in high-growth international healthcare markets.

Financially, Sahajanand Medical demonstrates a steady multi-year financial track record characterized by scaling revenues and improving operational efficiencies. Revenue from operations has exhibited a positive CAGR driven by expanding export volumes and higher adoption of premium vascular devices, while EBITDA margins have shown progressive expansion due to manufacturing efficiencies and scale economies. Profit after tax (PAT) trajectory reflects robust operational leverage despite continuous investments in clinical trials and regulatory compliance.

Valuation-wise, the issue is priced at a multiple that reflects its niche positioning as a global medical technology player compared to domestic and international medtech peers. Key metrics such as Return on Equity (ROE) and Return on Capital Employed (ROCE) reflect improving capital efficiency, while the net debt-to-equity ratio remains well-managed. The valuation framework balances the high entry barriers and proprietary R&D moat of the company against prevailing sector valuation benchmarks.

Key investment highlights include the company's rare global certifications, strong intellectual property backed by extensive clinical studies, and favorable secular tailwinds in the cardiovascular intervention market driven by aging demographics and rising healthcare access. Promoter alignment remains strong, with key stakeholders maintaining substantial skin in the game and a clear strategic vision for long-term value creation.

Principal risk factors include regulatory approval timelines in new geographies, potential pricing pressures in international tenders, foreign exchange volatility given its extensive global footprint, and customer concentration within specific hospital networks or distribution partners. Market sentiment, as reflected by healthy institutional participation and initial grey market trends, indicates constructive investor appetite for specialized healthcare plays.